Candidate Drug Treatments: The pathophysiology of potassium flux, coupled with the accessibility of potassium channels, the pharmacology of which is well characterized, has pointed to the possibility of targeting potassium channels as a therapeutic modality against cancer metastasis (9). This evidence concerns the gene KCNA3 and cancer.